From Fat Science: The Science Behind the New Wegovy Pill: One-On-One with Novo Nordisk’s Dr. Jason Brett., Feb 23, 2026 

Dr. Jason Brett of Novo Nordisk —

“And while we're kind of talking about this future, I'm very excited about the Cagrasema and the Amacretin pathway that Novo is exploring now. I've been a big fan of Amelin as a useful hormone in our body. And I've been noticing over the years, even since the age of simulant, different advantages that that carries.

And so I'm just excited about that pathway. And so I'd love to know anything that you can share with us about where we are with the development of those Amelin analogs.

Sure. Yeah. Thank you for that question.

So we have developed a long-acting Amelin analog called Cogrillentide. And I think you know that one of the challenges with Amelin is that it tends to fibrillate. And it has a very short half-life, like of about 12 minutes or so, right?

So we know that to make it drugable, we really need to have long-acting derivatives. So we've been able to really formulate a fixed-dose combination of our long-acting Amelin analog, Cogrillentide, with our once-weekly GLP-1 receptor agonist, Cymaglutide. And that's Cagri-Semma, what you referred to, Emily.

And we have completed two phase three pivotal trials in patients with obesity or overweight with comorbidity. And those are called the redefined trials. And in December, just a little over a month ago, we announced that we've submitted that file to the FDA for review and approval.

So we're to be expecting to hear something around the turn of the year and the 2026, 2027 time period. So I think we're very excited about that because really having a medication and a product that can target two overlapping but distinct mechanisms of action that are complementing each other, complementary mechanisms of action, that could really further meet expectations of patients and healthcare professionals where we're seeing even greater weight loss than the individual components alone. So when we look at the trials, if you look at, we define one, these are patients with obesity or overweight with comorbidity, but without diabetes.

When we analyze the data as if they took the medication as directed, so on treatment without rescue intervention, we're seeing weight loss over 68 weeks up to 22.7 percent weight loss. So a whole other magnitude that should be able to help even more patients who need even more robust weight loss. So a very exciting field.

Once again, it gets down to, we want to innovate, we want more options for patients, and health care professionals, and there'll be patients who will need other options.”

This podcast discusses the progress of trials (and FDA approval) of Cagrisema - combining semaglutide (2.4 mg) and cagrilintide (2.4 mg)